Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Abdelrahman Ahmed, Emmanuel Akintoye & Neelima Thati. (2019) Reducing substance abuse in patients receiving prescription opioids for chronic non-cancer pain: a quality improvement and patient safety study in a primary care setting. Journal of Community Hospital Internal Medicine Perspectives 9:3, pages 175-180.
Read now
Read now
Shannon Portillo, Danielle S. Rudes & Faye S. Taxman. (2016) The Transportability of Contingency Management in Problem-solving Courts. Justice Quarterly 33:2, pages 267-290.
Read now
Read now
PatrickM. Flynn, JamesV. Porto, JenniferL. Rounds-Bryant & PatriciaL. Kristiansen. (2002) Costs and Benefits of Methadone Treatment in DATOS- Part 1. Journal of Maintenance in the Addictions 2:1-2, pages 129-149.
Read now
Read now
Articles from other publishers (19)
Stephen Orme, Gary A. Zarkin, Jackson Luckey, Laura J. Dunlap, Matthew D. Novak, August F. Holtyn, Forrest Toegel & Kenneth Silverman. (2023) Cost and cost-effectiveness of abstinence contingent wage supplements. Drug and Alcohol Dependence 244, pages 109754.
Crossref
Crossref
Ali Jalali, Rulla M Tamimi, Sterling M McPherson & Sean M Murphy. (2022) Econometric Issues in Prospective Economic Evaluations Alongside Clinical Trials: Combining the Nonparametric Bootstrap With Methods That Address Missing Data. Epidemiologic Reviews 44:1, pages 67-77.
Crossref
Crossref
James Shearer, Hiong Tie & Sarah Byford. (2015) Economic evaluations of contingency management in illicit drug misuse programmes: A systematic review. Drug and Alcohol Review 34:3, pages 289-298.
Crossref
Crossref
Bach Xuan Tran & Long Thanh Nguyen. (2013) Impact of methadone maintenance on health utility, health care utilization and expenditure in drug users with HIV/AIDS. International Journal of Drug Policy 24:6, pages e105-e110.
Crossref
Crossref
John M. Roll, Gregory J. Madden, Richard Rawson & Nancy M. Petry. (2017) Facilitating the Adoption of Contingency Management for the Treatment of Substance Use Disorders. Behavior Analysis in Practice 2:1, pages 4-13.
Crossref
Crossref
David H. Epstein, John Schmittner, Annie Umbricht, Jennifer R. Schroeder, Eric T. Moolchan & Kenzie L. Preston. (2009) Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency. Drug and Alcohol Dependence 101:1-2, pages 92-100.
Crossref
Crossref
Mark K. Greenwald. (2013) OPIOID ABSTINENCE REINFORCEMENT DELAYS HEROIN LAPSE DURING BUPRENORPHINE DOSE TAPERING. Journal of Applied Behavior Analysis 41:4, pages 603-607.
Crossref
Crossref
Michael T. French, Ioana Popovici & Lauren Tapsell. (2008) The economic costs of substance abuse treatment: Updated estimates and cost bands for program assessment and reimbursement. Journal of Substance Abuse Treatment 35:4, pages 462-469.
Crossref
Crossref
Christopher M Doran. (2008) Economic Evaluation of Interventions to Treat Opiate Dependence. PharmacoEconomics 26:5, pages 371-393.
Crossref
Crossref
Xavier Bosch-Capblanch, Katharine Abba, Megan Prictor & Paul Garner. (2007) Contracts between patients and healthcare practitioners for improving patients' adherence to treatment, prevention and health promotion activities. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Jody Sindelar, Brian Elbel & Nancy M. Petry. (2007) What do we get for our money? Cost‐effectiveness of adding contingency management. Addiction 102:2, pages 309-316.
Crossref
Crossref
Marian Shanahan, Alys Havard, Maree Teesson, Katherine Mills, Anna Williamson & Joanne Ross. (2006) Patterns and costs of treatment for heroin dependence over 12 months: fndings from the Australian Treatment Outcome Study. Australian and New Zealand Journal of Public Health 30:4, pages 305-311.
Crossref
Crossref
M.D. Shanahan, C.M. Doran, E. Digiusto, J. Bell, N. Lintzeris, J. White, R. Ali, J.B. Saunders, R.P. Mattick & S. Gilmour. (2006) A cost-effectiveness analysis of heroin detoxification methods in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addictive Behaviors 31:3, pages 371-387.
Crossref
Crossref
Susan L. Ettner, David Huang, Elizabeth Evans, Danielle Rose Ash, Mary Hardy, Mickel Jourabchi & Yih-Ing Hser. (2006) Benefit-Cost in the California Treatment Outcome Project: Does Substance Abuse Treatment "Pay for Itself"?. Health Services Research 41:1, pages 192-213.
Crossref
Crossref
Carmen L. Masson, Paul G. Barnett, Karen L. Sees, Kevin L. Delucchi, Amy Rosen, Wynnie Wong & Sharon M. Hall. (2004) Cost and cost‐effectiveness of standard methadone maintenance treatment compared to enriched 180‐day methadone detoxification. Addiction 99:6, pages 718-726.
Crossref
Crossref
Mark H Pollack, Susan A Penava, Elisa Bolton, John J WorthingtonIIIIII, Gretchen Lanka Allen, Francisco J FarachJr.Jr. & Michael W Otto. (2002) A novel cognitive-behavioral approach for treatment-resistant drug dependence. Journal of Substance Abuse Treatment 23:4, pages 335-342.
Crossref
Crossref
Robert Rosenheck & Thomas Kosten. (2001) Buprenorphine for opiate addiction: potential economic impact. Drug and Alcohol Dependence 63:3, pages 253-262.
Crossref
Crossref
WALTER LING, ALICE HUBER & RICHARD A. RAWSON. (2009) New trends in opiate pharmacotherapy. Drug and Alcohol Review 20:1, pages 79-94.
Crossref
Crossref
William S. Cartwright. (2000) Cost-benefit analysis of drug treatment services: review of the literature. The Journal of Mental Health Policy and Economics 3:1, pages 11-26.
Crossref
Crossref